Published in J Cardiovasc Risk on August 01, 2001
Regulation of Lymphocyte Function by PPARgamma: Relevance to Thyroid Eye Disease-Related Inflammation. PPAR Res (2008) 0.90
Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis (2007) 0.90
The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice. PPAR Res (2007) 0.90
15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. Br J Cancer (2002) 0.86
Formononetin inhibited the inflammation of LPS-induced acute lung injury in mice associated with induction of PPAR gamma expression. Inflammation (2013) 0.85
The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. PPAR Res (2008) 0.85
Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes. PPAR Res (2010) 0.83
Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases. PPAR Res (2012) 0.81
PPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1. PPAR Res (2016) 0.77
Overview. PPAR and cardiovascular risk. J Cardiovasc Risk (2001) 0.75
Collagen Induced Arthritis in DBA/1J Mice Associates with Oxylipin Changes in Plasma. Mediators Inflamm (2015) 0.75
Relationship between Platelet PPARs, cAMP Levels, and P-Selectin Expression: Antiplatelet Activity of Natural Products. Evid Based Complement Alternat Med (2013) 0.75
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science (2001) 8.73
The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem (1997) 4.55
Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 4.39
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med (2001) 4.17
PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J (1996) 4.11
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem (1999) 3.57
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature (1998) 3.48
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res (1996) 3.36
Protective role of interleukin-10 in atherosclerosis. Circ Res (1999) 3.28
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem (1998) 3.27
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res (2000) 3.02
The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta (1996) 2.83
Transient increase in obese gene expression after food intake or insulin administration. Nature (1995) 2.79
Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol (2001) 2.66
Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem (2000) 2.18
Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem (1997) 2.18
Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem (2001) 2.11
Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol (1999) 2.05
Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem (2000) 1.95
Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation (1999) 1.88
Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem (1996) 1.88
Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest (1995) 1.88
Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem (1997) 1.84
Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol (1997) 1.82
Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta-analysis. J Nutr (1998) 1.74
Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest (1995) 1.74
Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem (1995) 1.66
p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J Biol Chem (1999) 1.66
CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation (2000) 1.65
The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. EMBO Rep (2001) 1.64
Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol (1999) 1.62
Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun (2004) 1.61
Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia (2000) 1.54
Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J Biol Chem (1995) 1.54
Transcriptional control of adipogenesis. Curr Opin Cell Biol (1998) 1.52
Leptin. Lancet (1998) 1.51
PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes (2001) 1.50
Schistosoma mansoni schistosomula reduce E-selectin and VCAM-1 expression in TNF-alpha-stimulated lung microvascular endothelial cells by interfering with the NF-kappaB pathway. Eur J Immunol (1999) 1.49
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest (2001) 1.47
Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol (2002) 1.47
Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis (1987) 1.47
Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem (1990) 1.46
Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids. J Biol Chem (1994) 1.45
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans (2006) 1.44
An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J Neurochem (1990) 1.43
Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation (1996) 1.43
Lipid traffic between high density lipoproteins and Plasmodium falciparum-infected red blood cells. J Cell Biol (1991) 1.43
The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. J Biol Chem (1989) 1.41
Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J Endocrinol (2006) 1.40
The OSBP-related protein family in humans. J Lipid Res (2001) 1.40
Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science (1996) 1.39
Distribution of lipid variables in subjects in Belfast, Northern Ireland and Taiyuan, P R China. Atherosclerosis (1993) 1.39
The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem (1998) 1.38
PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett (1998) 1.38
The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab (2005) 1.37
Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ Res (2005) 1.37
Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol (2001) 1.36
Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol (1999) 1.35
Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORalpha. Circulation (1998) 1.35
Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol (1995) 1.35
Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J Biol Chem (2001) 1.34
Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem (1992) 1.32
Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem Biophys Res Commun (1987) 1.30
Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100. J Biol Chem (1990) 1.30
Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem (2001) 1.28
Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest (1996) 1.28
Abundant adrenal-specific transcription of the human P450c21A "pseudogene". J Biol Chem (1993) 1.28
Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett (2000) 1.28
Cloning and sequencing of cDNAs encoding the human hepatocyte nuclear factor 4 indicate the presence of two isoforms in human liver. Gene (1994) 1.26
Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab (2000) 1.26
Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol (2000) 1.26
Circadian and glucocorticoid regulation of Rev-erbalpha expression in liver. Endocrinology (2000) 1.24
The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression. Proc Natl Acad Sci U S A (1996) 1.23
Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis (1996) 1.22
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest (1996) 1.22